公司资料
Verve Therapeutics 股价、新闻与催化剂
- 股票代码:
- VERV
- 交易所:
- NASDAQ
- 行业:
- Healthcare Services
- 所在地:
- United States
股价为何变动
目前无法获取 VERV 的收盘价变动背景。
公司概览
业务概览
Verve Therapeutics is a gene-editing and cardiovascular company focused on one-time treatments for atherosclerotic disease. It tries to bring the durability of genetic medicine into heart disease.
所在地与行业分类
Headquartered in the United States and listed on NASDAQ, Verve sits in advanced biotechnology.
商业模式特征
The business is driven by platform validation, early clinical data, and the long-term opportunity to create a genetic cardiovascular franchise.
生物医药行业定位
Verve is one of the more interesting cardiovascular gene-editing names because it could redefine how heart disease is treated.
未来催化剂
- Verve Therapeutics's catalysts are its cardiovascular base-editing programs, especially the PCSK9 and LPA work, where the next human data decide whether in vivo editing is ready for prime time. The company needs a clean step forward to keep the gene-editing story credible.
近期新闻
新闻标题由机器翻译，详情为英文原文。
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。